Drug Profile
Dasabuvir - AbbVie
Alternative Names: ABT-333; Exviera; Viekira Pak (dasabuvir combination therapy); VIEKIRA XRLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antivirals; Naphthalenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 13 May 2021 AbbVie completes the phase III TOPAZ-I trial in Hepatitis C (Combination therapy) in Algeria, Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Arabia, Spain, Sweden, Switzerland, Turkey and United Kingdom (PO) (NCT02219490)
- 13 May 2021 AbbVie completes the phase III TOPAZ II trial for Hepatitis C (Combination therapy, In adults, In the elderly) in USA (NCT02167945)
- 15 Sep 2020 No development reported - Phase-III for Hepatitis C (Combination therapy) in China (PO)